CivicaScript launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer.

Civica Rx Subsidiary Offers First Low-Cost Generic Drug in Outpatient Pharmacy Space, with More to Come

CivicaScript, a unit of hospital-owned nonprofit drug company Civica Rx, has launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer. The company will sell abiraterone to pharmacies at $160 for one month’s supply and recommends selling it to patients for no more than $171, a 6.9% mark-up. 

Patients with Medicare Part D—the most likely payor for medications treating this type of cancer—pay about $3,000 per month for abiraterone on average, CivicaScript says. A generic version was first released in 2018 but lacks sufficient market competition to make it affordable for most patients.

CivicaScript, a unit of hospital-owned nonprofit drug company Civica Rx, has launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report